Press Releases and Blog
Blog
Correcting the Record: Pharmacy Benefit Companies Support and Promote Generics and Biosimilars
Pharmacy benefit companies actively promote the use of generics and biosimilars. Take a look at the data on drug utilization: 90 percent of prescriptions dispensed
Experts Urge Lawmakers to Reject “Delinking” and Other Proposed Policies That Will Increase Prescription Drug Costs
In case you missed it, Ike Brannon, senior fellow at the Jack Kemp Foundation and former senior economist for the United States Treasury and U.S.
House Hearing Underscores Misguided Proposals Targeting Pharmacy Benefit Companies Will Increase Drug Prices and Play Into Big Pharma’s Self-Serving Agenda
In case you missed it, an expert witness who testified before the U.S. House Committee on Oversight and Accountability during a hearing yesterday on pharmacy
ICYMI: Economic Experts Explain the Misunderstood Role of Pharmacy Benefit Managers
Ike Brannon, former senior economist for the United States Treasury and U.S. Congress, and Anthony Lo Sasso, professor of economics at DePaul University, explain the
Just the Facts: Research and Analysis Finds Anti-PBM Legislation Does Not Lower Prescription Drug Costs for Patients
While debating important legislative proposals that can impact patients’ health and access to medications, the discussion should rely on solid facts and evidence. Today, we’re
Senator Rand Paul Sounds the Alarm on Legislation Targeting Pharmacy Benefits that will Actually Increase Prescription Drug Prices
As Congress reviews legislation targeting Americans’ pharmacy benefits, Members of Congress are raising concerns about the unintended risks of significantly increasing drug costs. In case
Press Releases
Senate Finance Committee Bill Will Cost Taxpayers and is a $10 Billion Giveaway to Big Pharma
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement today on legislation introduced by Senate Finance Committee members: The just-released Senate
National Bureau of Economic Research Working Paper: “Delinking” Proposals that Restrict PBM Incentives to Secure Rx Savings Will Increase Drug Prices and Provide $10B Giveaway for Big Pharma
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today issued the following statement on a new research paper, “Ending Pay for PBM Performance: Consequences
PCMA Statement on Legislation Introduced in the House of Representatives
(Washington, D.C.) — PCMA issued the following statement on legislation introduced in the House of Representatives: Legislation introduced in U.S. House of Representatives targeting pharmacy
PCMA Statement on the Tenth Circuit’s Decision in PCMA v. Mulready
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) applauds the recent ruling by the U.S. Court of Appeals for the Tenth Circuit in PCMA
PCMA Statement on House Ways and Means Committee and Senate Finance Committee Legislation
What Problem is Congress Trying to Solve? (Washington D.C.) – The Pharmaceutical Care Management Association released the following statement on today’s votes in the Senate
PCMA Statement on Federal Trade Commission Vote on PBM Advocacy
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on today’s vote by the Federal Trade Commission (FTC): “We agree with
Correcting the Record: Pharmacy Benefit Companies Support and Promote Generics and Biosimilars
Pharmacy benefit companies actively promote the use of generics and biosimilars. Take a look at the data on drug utilization: 90 percent of prescriptions dispensed
Experts Urge Lawmakers to Reject “Delinking” and Other Proposed Policies That Will Increase Prescription Drug Costs
In case you missed it, Ike Brannon, senior fellow at the Jack Kemp Foundation and former senior economist for the United States Treasury and U.S.
House Hearing Underscores Misguided Proposals Targeting Pharmacy Benefit Companies Will Increase Drug Prices and Play Into Big Pharma’s Self-Serving Agenda
In case you missed it, an expert witness who testified before the U.S. House Committee on Oversight and Accountability during a hearing yesterday on pharmacy
ICYMI: Economic Experts Explain the Misunderstood Role of Pharmacy Benefit Managers
Ike Brannon, former senior economist for the United States Treasury and U.S. Congress, and Anthony Lo Sasso, professor of economics at DePaul University, explain the
Just the Facts: Research and Analysis Finds Anti-PBM Legislation Does Not Lower Prescription Drug Costs for Patients
While debating important legislative proposals that can impact patients’ health and access to medications, the discussion should rely on solid facts and evidence. Today, we’re
Senator Rand Paul Sounds the Alarm on Legislation Targeting Pharmacy Benefits that will Actually Increase Prescription Drug Prices
As Congress reviews legislation targeting Americans’ pharmacy benefits, Members of Congress are raising concerns about the unintended risks of significantly increasing drug costs. In case
New Brookings Analysis Concludes Legislation Targeting Pharmacy Benefit Companies Will Not Lower Prescription Drug Costs and Actually Weakens Negotiating Power Against Big Pharma
In case you missed it, the Brookings Institution released a new analysis, “A Brief Look At Current Debates About Pharmacy Benefit Managers,” which provides an
ICYMI: PCMA Rx Research Corner Blog Post: Dr. Lawton Robert Burns Sheds Light on the Role of PBMs
“PBMs promote competition in healthcare and help to reduce prices,” said Lawton Robert Burns Hot Off the Presses: University of Pennsylvania Wharton School professor Lawton
ICYMI: Pharmacy Benefit Managers Are Not To Blame For Rising Drug Prices
PCMA Urges Congress to Listen to Constituents and Address Rising Drug Prices In case you missed it, JC Scott, president and CEO of the Pharmaceutical
ICYMI: Costello: Targeting Pharmacy Benefits Would Raise Drug Costs
In case you missed it, former U.S. Representative for Pennsylvania’s 6th Congressional District Ryan Costello discusses how recent legislation targeting pharmacy benefit companies will raise
